RET and medullary thyroid gland carcinoma: To assess the potential of patient-derived iPSCs harboring inherited mutations as an accurate model of RET-driven NSCLC, we employed an iPS cell line derived from a patient carrying RETC634Y mutation (iRETC634Y) who developed medullary thyroid carcinoma (MTC) [34] Additionally, we included an isogenic CRISPR/Cas9-corrected iPSC line (iRETCTRL) as a control [35].